Brian Kim, MBA, on Multiomic Single-Cell Sequencing and the Ebbs and Flows of the Gene Therapy Field
The CEO of Mission Bio discussed the company’s single cell assay platform in the context of the broader developing field cell and gene therapy field.
“I think this is an interesting time we're living in right now and cell and gene therapy is going through a transition period right now, but I think it's really important to note that it's a transition period. I don't think people should really lose too much sleep that this is going to go away. A lot of drug modalities and technologies have these ebbs and flows, but we just saw this morning there was an announcement by the New York Times that a little baby was saved with a CRISPR-based therapeutic for a very rare genetic disorder that this child had. When you see things like that happening with patients with the therapies that we have right now, you know that it's going to go someplace in the future.”
Mission Bio is seeking to overcome limitations of bulk sequencing and standard single cell sequencing methods through the use of its Tapestri platform for single cell sequencing. At the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held May 13 to 17, 2024, in New Orleans, LA, the company gave several presentations related to its platform and the ways in which it is contributing to the development of the field of cell and gene therapy.
At the conference, CGTLive® spoke with Brian Kim, MBA, the chief executive officer of Mission Bio, to learn more. Kim explained that the company offers a single-cell multiomic platform focused on validation for therapeutic and diagnostic purposes and highlighted the presentations the company gave at ASGCT this year. Kim also took a broader view and emphasized that despite current challenges in cell and gene therapy, the field is progressing, with recent news of patient successes reinforcing its potential. He pointed out that Mission Bio remains committed for the long haul, having supported over 17 clinical trials and working to expand adoption of its assays. Future plans for the company include adding targeted gene expression to their platform and seeking to foster more collaborations.
Click here to view more coverage of the 2025 ASGCT Annual Meeting.
Eugenio Galli, MD, PhD, on Reexamining Frailty as a Barrier to CAR-T Treatment
June 16th 2025The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.
